Drug-maker Wockhardt Ltd formalised a deal with the US-based Sheffield Bio-Science to supply recombinant insulin in cell culture markets, across the world.
Sheffield Bio-Science, a Kerry Group Business company, will have exclusive sales and distribution rights to supply recombinant insulin in designated cell-culture markets estimated at $ 50 million, a Wockhardt note said.
As a part of the alliance, over a period of time, Wockhardt would develop and supply Animal Component Free (ACF) recombinant insulin for distribution in cell-culture markets, the note added.
On Monday, the company's shares ended up 0.36 per cent at Rs 364 on the BSE.